Della Pia Alexandra, Zhao Charles, Jandir Parul, Gupta Amolika, Batistick Mark, Kim Gee Youn Geeny, Xia Yi, Ahn Jaeil, Magarelli Gabriella, Lukasik Brittany, Leslie Lori A, Goy Andre H, Ip Andrew, Feldman Tatyana A
Hackensack University Medical Center, Hackensack, NJ 07601, USA.
Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ 08854, USA.
Cancers (Basel). 2022 Aug 31;14(17):4252. doi: 10.3390/cancers14174252.
Lymphoma patients are at greater risk of severe consequences from COVID-19 infection, yet most reports of COVID-19-associated outcomes were published before the advent of COVID-19 vaccinations and monoclonal antibodies (mAbs). In this retrospective study, we report the real-world outcomes of 68 lymphoma or CLL patients who developed COVID-19 infection during the omicron surge in the US. We found that 34% of patients were hospitalized as a result of COVID-19 infection. The death rate due to COVID-19 was 9% (6/68) in the overall population and 26% (6/23) in hospitalized patients. During the preintervention COVID-19 era, the mortality rate reported in cancer patients was 34%, which increased to 60.2% in hospitalized patients. Thus, the death rates in our study were much lower when compared to those in cancer patients earlier in the pandemic, and may be attributed to modern interventions. In our study, 60% (18/30) of patients with serology data available did not develop anti-COVID-19 spike protein antibodies following vaccination. Most patients (74%, 17/23) who were hospitalized due to COVID-19 infection did not receive COVID-19 mAb treatment. Our results pointed to the importance of humoral immunity and the protective effect of COVID-19 mAbs in improving outcomes in lymphoma patients.
淋巴瘤患者感染新冠病毒后出现严重后果的风险更高，但大多数关于新冠病毒相关结局的报告是在新冠疫苗和单克隆抗体（mAbs）出现之前发表的。在这项回顾性研究中，我们报告了在美国奥密克戎毒株激增期间感染新冠病毒的68例淋巴瘤或慢性淋巴细胞白血病（CLL）患者的真实世界结局。我们发现，34%的患者因感染新冠病毒而住院。总体人群中新冠病毒导致的死亡率为9%（6/68），住院患者中为26%（6/23）。在新冠病毒感染前的时期，癌症患者报告的死亡率为34%，住院患者中这一比例升至60.2%。因此，与疫情早期癌症患者的死亡率相比，我们研究中的死亡率要低得多，这可能归因于现代干预措施。在我们的研究中，有血清学数据的患者中，60%（18/30）在接种疫苗后未产生抗新冠病毒刺突蛋白抗体。大多数因感染新冠病毒而住院的患者（74%，17/23）未接受新冠病毒单克隆抗体治疗。我们的结果指出了体液免疫的重要性以及新冠病毒单克隆抗体在改善淋巴瘤患者结局方面的保护作用。
